CELLECTIS (ALCLS.PA) Fundamental Analysis & Valuation

EPA:ALCLS • FR0010425595

Current stock price

3.63 EUR
+0.44 (+13.86%)
Last:

This ALCLS.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALCLS.PA Profitability Analysis

1.1 Basic Checks

  • ALCLS had negative earnings in the past year.
  • In the past year ALCLS has reported a negative cash flow from operations.
  • In the past 5 years ALCLS always reported negative net income.
  • In the past 5 years ALCLS reported 4 times negative operating cash flow.
ALCLS.PA Yearly Net Income VS EBIT VS OCF VS FCFALCLS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • With a Return On Assets value of -26.22%, ALCLS perfoms like the industry average, outperforming 46.43% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -112.16%, ALCLS is in line with its industry, outperforming 41.67% of the companies in the same industry.
Industry RankSector Rank
ROA -26.22%
ROE -112.16%
ROIC N/A
ROA(3y)-20.21%
ROA(5y)-26.23%
ROE(3y)-78.81%
ROE(5y)-75.6%
ROIC(3y)N/A
ROIC(5y)N/A
ALCLS.PA Yearly ROA, ROE, ROICALCLS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • ALCLS has a worse Gross Margin (26.95%) than 61.90% of its industry peers.
  • In the last couple of years the Gross Margin of ALCLS has grown nicely.
  • ALCLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y14.03%
ALCLS.PA Yearly Profit, Operating, Gross MarginsALCLS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. ALCLS.PA Health Analysis

2.1 Basic Checks

  • ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ALCLS has more shares outstanding
  • ALCLS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ALCLS is higher compared to a year ago.
ALCLS.PA Yearly Shares OutstandingALCLS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
ALCLS.PA Yearly Total Debt VS Total AssetsALCLS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • ALCLS has an Altman-Z score of -0.36. This is a bad value and indicates that ALCLS is not financially healthy and even has some risk of bankruptcy.
  • ALCLS has a worse Altman-Z score (-0.36) than 60.71% of its industry peers.
  • ALCLS has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 1.34, ALCLS is doing worse than 63.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Altman-Z -0.36
ROIC/WACCN/A
WACC5.95%
ALCLS.PA Yearly LT Debt VS Equity VS FCFALCLS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • ALCLS has a Current Ratio of 1.62. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.
  • ALCLS has a Current ratio of 1.62. This is in the lower half of the industry: ALCLS underperforms 63.10% of its industry peers.
  • A Quick Ratio of 1.62 indicates that ALCLS should not have too much problems paying its short term obligations.
  • The Quick ratio of ALCLS (1.62) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.62
ALCLS.PA Yearly Current Assets VS Current LiabilitesALCLS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ALCLS.PA Growth Analysis

3.1 Past

  • ALCLS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -91.43%.
  • Looking at the last year, ALCLS shows a very strong growth in Revenue. The Revenue has grown by 74.59%.
  • The Revenue has been growing slightly by 5.97% on average over the past years.
EPS 1Y (TTM)-91.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-425%
Revenue 1Y (TTM)74.59%
Revenue growth 3Y45.72%
Revenue growth 5Y5.97%
Sales Q2Q%-19.51%

3.2 Future

  • ALCLS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -23.99% yearly.
  • The Revenue is expected to grow by 22.01% on average over the next years. This is a very strong growth
EPS Next Y-63.57%
EPS Next 2Y-44.24%
EPS Next 3Y-23.99%
EPS Next 5YN/A
Revenue Next Year-15.14%
Revenue Next 2Y-7.59%
Revenue Next 3Y-25.71%
Revenue Next 5Y22.01%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALCLS.PA Yearly Revenue VS EstimatesALCLS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
ALCLS.PA Yearly EPS VS EstimatesALCLS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. ALCLS.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALCLS. In the last year negative earnings were reported.
  • Also next year ALCLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALCLS.PA Price Earnings VS Forward Price EarningsALCLS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCLS.PA Per share dataALCLS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • ALCLS's earnings are expected to decrease with -23.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-44.24%
EPS Next 3Y-23.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALCLS.PA Dividend Analysis

5.1 Amount

  • No dividends for ALCLS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALCLS.PA Fundamentals: All Metrics, Ratios and Statistics

CELLECTIS

EPA:ALCLS (4/14/2026, 7:00:00 PM)

3.63

+0.44 (+13.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19
Earnings (Next)04-30
Inst Owners8.74%
Inst Owner ChangeN/A
Ins Owners2.34%
Ins Owner ChangeN/A
Market Cap261.69M
Revenue(TTM)128.78M
Net Income(TTM)-85.13M
Analysts84.62
Price Target6.63 (82.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.64%
Min EPS beat(2)1.78%
Max EPS beat(2)103.5%
EPS beat(4)4
Avg EPS beat(4)33.78%
Min EPS beat(4)1.78%
Max EPS beat(4)103.5%
EPS beat(8)8
Avg EPS beat(8)53.59%
EPS beat(12)10
Avg EPS beat(12)29.41%
EPS beat(16)13
Avg EPS beat(16)26.11%
Revenue beat(2)1
Avg Revenue beat(2)209.09%
Min Revenue beat(2)-4.74%
Max Revenue beat(2)422.92%
Revenue beat(4)2
Avg Revenue beat(4)115.13%
Min Revenue beat(4)-20.05%
Max Revenue beat(4)422.92%
Revenue beat(8)6
Avg Revenue beat(8)103.35%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.72%
EPS NQ rev (3m)7.63%
EPS NY rev (1m)7.21%
EPS NY rev (3m)7.21%
Revenue NQ rev (1m)-22.41%
Revenue NQ rev (3m)-39.26%
Revenue NY rev (1m)-8.03%
Revenue NY rev (3m)-25.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.37
P/FCF N/A
P/OCF N/A
P/B 4.03
P/tB 4.06
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS1.53
BVpS0.9
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.22%
ROE -112.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.95%
FCFM N/A
ROA(3y)-20.21%
ROA(5y)-26.23%
ROE(3y)-78.81%
ROE(5y)-75.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y14.03%
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.61%
Cap/Sales 2.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 1.62
Altman-Z -0.36
F-Score3
WACC5.95%
ROIC/WACCN/A
Cap/Depr(3y)14.26%
Cap/Depr(5y)35.03%
Cap/Sales(3y)7.97%
Cap/Sales(5y)16.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-91.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-425%
EPS Next Y-63.57%
EPS Next 2Y-44.24%
EPS Next 3Y-23.99%
EPS Next 5YN/A
Revenue 1Y (TTM)74.59%
Revenue growth 3Y45.72%
Revenue growth 5Y5.97%
Sales Q2Q%-19.51%
Revenue Next Year-15.14%
Revenue Next 2Y-7.59%
Revenue Next 3Y-25.71%
Revenue Next 5Y22.01%
EBIT growth 1Y57.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-82.17%
EBIT Next 3Y-46.6%
EBIT Next 5YN/A
FCF growth 1Y-324.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-271.39%
OCF growth 3YN/A
OCF growth 5YN/A

CELLECTIS / ALCLS.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CELLECTIS?

ChartMill assigns a fundamental rating of 2 / 10 to ALCLS.PA.


What is the valuation status of CELLECTIS (ALCLS.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to CELLECTIS (ALCLS.PA). This can be considered as Overvalued.


How profitable is CELLECTIS (ALCLS.PA) stock?

CELLECTIS (ALCLS.PA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CELLECTIS?

The Earnings per Share (EPS) of CELLECTIS (ALCLS.PA) is expected to decline by -63.57% in the next year.